Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies-Reference-Cited by-同舟云学术

Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies

Published:2022-05-24 Issue:11 Volume:65 Page:8011-8028
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhang Jingbo¹²,Jiang Huimin¹,Lin Songwen¹²,Wu Deyu¹²,Tian Hua¹²,Jiang Lin¹²,Cui Yiman¹²,Jin Jing¹,Chen Xiaoguang¹,Xu Heng¹²^ORCID

Affiliation:

1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

2. Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Funder

Ministry of Science and Technology of the People's Republic of China

Chinese Academy of Medical Sciences

Central University Basic Research Fund of China

National Natural Science Foundation of China

Beijing Outstanding Young Scientist Program

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00530